News from Novartis on the EU approval of Mayzent (siponimod) for adult patients with SPMS with active disease
This website is intended for healthcare professionals
News from Novartis on the EU approval of Mayzent (siponimod) for adult patients with SPMS with active disease
© 2024 ACNR. Published by Whitehouse Publishing. Read our Privacy and Cookie Policy. Website by Sugar Web.
Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified.
For UK-based specialists, sign up for our journal mailing list.
URL here
You are now leaving the ACNR website, please click the "Continue" button below. If you do not wish to leave, please close this pop-up.